Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
ALDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $7.20
Previous CloseN/A
Volume102.94K
Average Volume (3M)2.41M
Market Cap
$114.04M
Enterprise Value$126.91M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding59,708,652
10 Day Avg. Volume5,705,851
30 Day Avg. Volume2,413,989
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$9.67Price Target Upside406.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company has approximately $101M in cash and expects the remaining costs for the ongoing trials to be only around $6M, which keeps the company in a favorable financial position.
Partnership OpportunityFDA approval would likely lead AbbVie to exercise the option to co-commercialize reproxalap, triggering a $100M milestone payment to Aldeyra.
Pipeline PotentialBroader RASP pipeline offers catalysts and programs not in the spotlight, with potential applications beyond ocular inflammatory diseases to systemic immune-mediated and metabolic diseases.
Bears Say
Approval UncertaintyThe probability of success for Reproxalap has been decreased from 85% to 75%, reflecting increased uncertainty in the approval process.
Manufacturing RiskThere is a 15% probability of a manufacturing-related Complete Response Letter, which could jeopardize the option.
Regulatory DelayThe FDA has delayed the approval of Reproxalap due to concerns over trial results, which has pushed the expected drug launch out by a year.
---
Ownership Overview
18.96% Insiders
10.98% Mutual Funds
26.56% Other Institutional Investors
34.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $114.04M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.031.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 59,708,652 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
---
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (406.28% Upside)
$9.67 (406.28% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 650.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.59%
12-Months-Change
Fundamentals
Return on Equity
-58.54%
Trailing 12-Months
Asset Growth
-29.48%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
---
ALDX Stock 12 Month Forecast
Average Price Target
$9.67
▲(406.28% Upside)
Technical Analysis
Nektar Therapeutics
―
Larimar Therapeutics
―
Kodiak Sciences
―
RAPT Therapeutics
―
Nkarta
―
Best Analysts Covering ALDX
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+15.25%
reiterated a buy rating 14 days ago
Copying Catherine Novack's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.25% per trade.
---